Fri, Mar 28, 8:49 PM (29 days ago)
**QHSLab, Inc. (USAQ) 2024 Financial Summary** **Financial Performance:** - **Revenue:** $2,131,926 (2024) vs. $1,408,995 (2023) - Driven by Allergy Diagnostic Kits and Integrated Service Program (ISP) revenues. - **Net Income:** -$259,239 (2024) vs. -$468,362 (2023) - **Gross Profit:** $1,357,890 (2024) vs. $793,607 (2023) - Gross margin increased to 63.7% (2024) from 56.3% (2023). - **Operating Expenses:** - Sales and Marketing: $509,065 (2024) vs. $488,537 (2023) - General and Administrative: $276,496 (2024) vs. $259,108 (2023) - Research and Development: $294,479 (2024) vs. $214,008 (2023) - **Interest Expense:** $465,055 (2024) vs. $230,494 (2023) - Increased due to default interest on notes. **Strategic Overview:** - Focus on enabling primary care physicians (PCPs) to increase revenues through value-based tools. - Key products: QHSLab (SaaS platform), Allergi End® (allergy diagnostics and immunotherapy). - Expansion plans include additional point-of-care diagnostics, treatments, and digital medicine programs. **Future Outlook:** - Plans to increase revenues by charging physicians for QHSLab usage and expanding user base. - Continued investment in R&D and marketing to drive growth. **Risk Factors:** - High leverage and dependence on additional financing. - Material weaknesses in internal controls. - Dependence on key personnel and strategic partnerships. - Regulatory and compliance risks. **Financial Condition:** - Highly leveraged with significant debt. - Positive cash flow from operations in 2024 but negative in 2023. - Substantial doubt about the ability to continue as a going concern. **Market Position:** - Listed on OTCQB under the symbol USAQ. - Limited trading volume and market liquidity. - Stock price volatility due to financial performance and market conditions.